Researchers at Michigan State University have identified a protein, TPPP3, that allows ovarian cancer cells to resist chemotherapy by stabilizing their internal structural scaffolding. Published in Cell Reports, the study reveals that blocking this protein restores the effectiveness of drugs like cisplatin. By targeting the “tubulin code” rather than just DNA, scientists aim to prevent cancer recurrence and reduce common treatment side effects.
How does TPPP3 enable chemotherapy resistance?
Ovarian cancer cells survive chemotherapy by fortifying their internal architecture, according to Sachi Horibata, an assistant professor in the MSU College of Human Medicine. The protein TPPP3—tubulin polymerization promoting protein 3—acts as a protective shield. When cancer cells express high levels of TPPP3, they effectively stabilize their microtubules, the internal scaffolding that cells rely on to maintain shape and survive under stress. While drugs like cisplatin typically work by damaging DNA, the research shows these drugs also target microtubules; TPPP3 prevents the drugs from successfully disrupting this structure.
Cisplatin, one of the most widely used chemotherapy drugs globally, was discovered at Michigan State University in 1965. It remains a gold standard for treating various cancers today.
Why does cancer return after treatment?
Patients are often declared cancer-free, only to face a recurrence later because tumors adapt to survive initial therapies. Horibata’s research indicates that cancer cells possess the ability to reprogram the “tubulin code,” a series of structural adjustments that reinforce microtubules. By shifting the focus from DNA repair to these physical structural changes, researchers are uncovering why tumors return stronger. Patients with lower levels of TPPP3 consistently showed better responses to treatment and longer survival rates in the study’s findings.
How will this change future treatment strategies?
The discovery of TPPP3 opens the door to personalized medicine rather than replacing existing chemotherapy regimens. Researchers are currently exploring two primary paths: developing drugs specifically designed to inhibit TPPP3 and utilizing the protein as a biomarker to identify patients at high risk of resistance before they begin treatment. Because microtubules are essential for healthy cells, understanding this mechanism may also provide insight into mitigating common chemotherapy side effects, such as nerve damage, hearing loss, and hair loss.
Talk to your oncologist about clinical trials involving biomarker testing. As research progresses, identifying specific protein expressions like TPPP3 may help tailor chemotherapy combinations to individual patient needs.
Frequently Asked Questions
- What is TPPP3? It is a protein that helps cancer cells stabilize their internal scaffolding, making them more resilient to chemotherapy drugs like cisplatin.
- Can chemotherapy resistance be reversed? In laboratory models, researchers found that removing or blocking the TPPP3 protein significantly restored the cancer cells’ sensitivity to chemotherapy.
- Does this affect other types of cancer? While this study focused on ovarian cancer, researchers are planning future studies to determine if this mechanism plays a role in the resistance of other cancer types.
Are you interested in the latest advancements in oncology research? Subscribe to our newsletter for updates on precision health and breakthroughs in cancer treatment.
Keep reading